Status:
COMPLETED
Radiation Therapy and Cardiac Enzymes
Lead Sponsor:
M.D. Anderson Cancer Center
Conditions:
Tumor
Eligibility:
All Genders
18+ years
Brief Summary
The goal of this clinical research study is to learn if the radiation that you are receiving will result in an increase in certain proteins produced by the heart called cardiac biomarkers.
Detailed Description
Cardiac Biomarkers: Cardiac biomarkers are proteins made by the heart. When cardiac biomarkers are above normal levels, there may be damage to the heart. The relationship between cardiac biomarkers a...
Eligibility Criteria
Inclusion
- A total of thirty patients will be prospectively enrolled in this study. Patients with tumors in the chest including histologically proven primary lung cancer, esophageal cancer, thymoma or mesothelioma to be treated with RT with or without concurrent chemotherapy to a final dose of \>/=45 Gy will be included in this study.
- Patients with tumors in close proximity to the heart where the treating radiation oncologist anticipates the mean cardiac dose will exceed 20Gy.
- All patients must sign a study-specific informed consent form. If the patient's mental status precludes his/her giving informed consent, written informed consent may be given by the patient's legal representative.
- Age \>/= 18
- Women of childbearing potential (A woman of child-bearing potential is a sexually mature woman who has not undergone a hysterectomy or who has not been naturally postmenopausal for at least 24 consecutive months \[i.e., who has had menses at any time in the preceding 24 consecutive months\]. For women of childbearing potential, a blood pregnancy test must be performed within 72 hours prior to the start of protocol treatment.
Exclusion
- Patients who receive 5-fluorouracil or adriamycin as part of their chemotherapy regimen.
- Patients with recent myocardial infarction in the past month, decompensated heart failure or myocarditis/pericarditis in the past month
- Patients with renal failure indicated by a serum creatinine level of \>/= 2.0.
- Patients in the intensive care unite (ICU).
- Patients with systemic sepsis.
- Patients with acute pulmonary embolism in the past month.
- Women who are pregnant or nursing are not eligible as treatment involves unforeseeable risks to the fetus or child.
- Inability to obtain histologic proof of malignancy.
Key Trial Info
Start Date :
October 6 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 21 2016
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00777751
Start Date
October 6 2008
End Date
November 21 2016
Last Update
January 10 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030